A three-signal model of T-cell lymphoma pathogenesis

American Journal of Hematology

Volumn 91, Issue 1, 2016, Pages 113-122

  Wilcox, Ryan A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CD3 ANTIGEN; CYTOKINE; INDUCIBLE T CELL COSTIMULATOR; JANUS KINASE; LYMPHOCYTE ANTIGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C THETA; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; STAT PROTEIN; T LYMPHOCYTE RECEPTOR; ANTINEOPLASTIC AGENT; CD28 ANTIGEN; ICOS PROTEIN, HUMAN; TNFRSF4 PROTEIN, HUMAN;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNOPATHOGENESIS; MOLECULAR PATHOLOGY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; TUMOR MICROENVIRONMENT; GENETICS; IMMUNOLOGY; LYMPHOMA, T-CELL; MOLECULARLY TARGETED THERAPY; T LYMPHOCYTE RECEPTOR GENE;

ANTIGENS, CD28; ANTINEOPLASTIC AGENTS; CYTOKINES; GENES, T-CELL RECEPTOR; HUMANS; INDUCIBLE T-CELL CO-STIMULATOR PROTEIN; LYMPHOMA, T-CELL; MOLECULAR TARGETED THERAPY; RECEPTORS, OX40; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84954362536     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24203     Document Type: Article

References (100)

1. Brownlie RJ, Zamoyska R. T cell receptor signalling networks: Branched, diversified and bounded. Nat Rev Immunol 2013; 13:257-269.
2. Andreotti AH, Schwartzberg PL, Joseph RE, Berg LJ. Tcell signaling regulated by the Tec family kinase, Itk. Cold Spring Harbor Perspect Biol 2010; 2:a002287.
3. Singleton KL, Gosh M, Dandekar RD, Au-Yeung BB, et al. Itk controls the spatiotemporal organization of T cell activation. Sci Signal 2011; 4:ra66.
4. Weissman IL, McGrath MS. Retrovirus lymphomagenesis: Relationship of normal immune receptors to malignant cell proliferation. Curr Top Microbiol Immunol 1982; 98:103-112.
5. Briski R, Feldman AL, Bailey NG, Lim MS, et al. The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. Blood Cancer J 2014; 4:e214.
6. Geissinger E, Sadler P, Roth S, Grieb T, et al. Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations. Haematologica 2010; 95:1697-1704.
7. Rodriguez-Pinilla SM, Sanchez ME, Rodriguez J, Garcia JF, et al. Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas. Blood Cancer J 2013; 3:e111.
8. Liang PI, Chang ST, Lin MY, Hsieh YC, et al. Angioimmunoblastic T-cell lymphoma in Taiwan shows a frequent gain of ITK gene. Int J Clin Exp Pathol 2014; 7:6097-6107.
9. Wilcox RA, Wada DA, Ziesmer SC, Elsawa SF, et al. Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood 2009 ; 114:2936-2944.
10. Wang T, Feldman AL, Wada DA, Lu Y, et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood 2014;123:3007-3015.
11. Berger CL, Hanlon D, Kanada D, Dhodapkar M, et al. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood 2002 ; 99:2929-2939.
12. Chen J, Petrus M, Bryant BR, Nguyen VP, et al. Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia. Blood. 2010 ; 116:5948-5956.
13. Wang X, Werneck MB, Wilson BG, Kim HJ, et al. TCR-dependent transformation of mature memory phenotype T cells in mice. J Clin Invest 2011; 121:3834-3845.
14. Serwold T, Hochedlinger K, Swindle J, Hedgpeth J, et al. Tcell receptor-driven lymphomagenesis in mice derived from a reprogrammed T cell. Proc Natl Acad Sci USA 2010;107:18939-18943.
15. Hagenbeek TJ, Spits H. Tcell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus. Leukemia 2008; 22:608-619.
16. Bug S, Durig J, Oyen F, Klein-Hitpass L, et al. Recurrent loss, but lack of mutations, of the SMARCB1 tumor suppressor gene in T-cell prolymphocytic leukemia with TCL1A-TCRAD juxtaposition. Cancer Genet Cytogenet 2009; 192:44-47.
17. Di Sabatino A, Biagi F, Gobbi PG, Corazza GR. How I treat enteropathy-associated T-cell lymphoma. Blood 2012 ; 119:2458-2468.
18. Jahan-Tigh RR, Huen AO, Lee GL, Pozadzides JV, et al. Hydrochlorothiazide and cutaneous T cell lymphoma: prospective analysis and case series. Cancer 2013; 119:825-831.
19. Litvinov IV, Jones DA, Sasseville D, Kupper TS. Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma. Clin Cancer Res 2010; 16:2106-2114.
20. Clemente MJ, Przychodzen B, Jerez A, Dienes BE, et al. Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes. Blood 2013;122:4077-4085.
21. Vonderheid EC, Boselli CM, Conroy M, Casaus L, et al. Evidence for restricted Vbeta usage in the leukemic phase of cutaneous T cell lymphoma. J Invest Dermatol 2005; 124:651-661.
22. Feldman AL, Dogan A, Smith DI, Law ME, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 2011; 117:915-919.
23. Li JP, Yang CY, Chuang HC, Lan JL, et al. The phosphatase JKAP/DUSP22 inhibits T-cell receptor signalling and autoimmunity by inactivating Lck. Nat Commun 2014; 5:3618.
24. Alonso A, Merlo JJ, Na S, Kholod N, et al. Inhibition of T cell antigen receptor signaling by VHR-related MKPX (VHX), a new dual specificity phosphatase related to VH1 related (VHR). J Biol Chem 2002; 277:5524-5528.
25. Streubel B, Vinatzer U, Willheim M, Raderer M, et al. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma.[see comment]. Leukemia. 2006; 20:313-318.
26. Hussain A, Mohammad DK, Gustafsson MO, Uslu M, et al. Signaling of the ITK (interleukin 2-inducible T cell kinase)-SYK (spleen tyrosine kinase) fusion kinase is dependent on adapter SLP-76 and on the adapter function of the kinases SYK and ZAP70. J Biol Chem 2013; 288:7338-7350.
27. Pechloff K, Holch J, Ferch U, Schweneker M, et al. The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma. J Exp Med 2010; 207:1031-1044.
28. Dierks C, Adrian F, Fisch P, Ma H, et al. The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease. Cancer Res 2010; 70:6193-6204.
29. Bach MP, Hug E, Werner M, Holch J, et al. Premature terminal differentiation protects from deregulated lymphocyte activation by ITK-Syk. J Immunol 2014; 192:1024-1033.
30. Feldman AL, Sun DX, Law ME, Novak AJ, et al. Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas. Leukemia 2008;22:1139-1143.
31. Palomero T, Couronne L, Khiabanian H, Kim MY, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 2014; 46:166-170.
32. Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 2014; 46:171-175.
33. Yoo HY, Sung MK, Lee SH, Kim S, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet 2014; 46:371-375.
34. Yu Y, Smoligovets AA, Groves JT. Modulation of T cell signaling by the actin cytoskeleton. J Cell Sci 2013; 126:1049-1058.
35. Su IH, Dobenecker MW, Dickinson E, Oser M, et al. Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 2005 ; 121:425-436.
36. Shi M, Shahsafaei A, Liu C, Yu H, et al. Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases. Leuk Lymphoma 2014; 30:1-5.
37. Vaque JP, Gomez-Lopez G, Monsalvez V, Varela I, et al. PLCG1 mutations in cutaneous T-cell lymphomas. Blood 2014; 123:2034-2043.
38. Boomer JS, Green JM. An enigmatic tail of CD28 signaling. Cold Spring Harbor Perspect Biol 2010; 2:a002436. PubMed PMID: 20534709.
39. McCusker ME, Garifallou M, Bogen SA. Sezary lineage cells can be induced to proliferate via CD28-mediated costimulation. J Immunol 1997; 158:4984-4991.
40. Rohr J, Guo S, Hu D, Bouska A, et al. CD28 mutations in peripheral T-cell lymphomagenesis and progression. Blood Annu Meet Abstr 2014; 124:1681.
41. Sekulic A, Liang WS, Tembe W, Izatt T, et al. Personalized treatment of Sezary syndrome by targeting a novel CTLA4:CD28 fusion. Mol Genet Genomic Med 2015; 3:130-136.
42. Zhang Q, Wang HY, Wei F, Liu X, et al. Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner. J Immunol 2014 ; 192:2913-2919.
43. Wilcox RA, Ansell SM, Lim MS, Zou W, et al. The B7 homologues and their receptors in hematologic malignancies. Eur J Haematol 2012; 88:465-475.
44. Fos C, Salles A, Lang V, Carrette F, et al. ICOS ligation recruits the p50alpha PI3K regulatory subunit to the immunological synapse. J Immunol 2008 ; 181:1969-1977.
45. Gigoux M, Shang J, Pak Y, Xu M, et al. Inducible costimulator promotes helper T-cell differentiation through phosphoinositide 3-kinase. Proc Natl Acad Sci USA 2009; 106:20371-20376.
46. Li J, Heinrichs J, Leconte J, Haarberg K, et al. Phosphatidylinositol 3-kinase-independent signaling pathways contribute to ICOS-mediated T cell costimulation in acute graft-versus-host disease in mice. J Immunol 2013; 191:200-207.
47. Choi YS, Kageyama R, Eto D, Escobar TC, et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity 2011 ; 34:932-946.
48. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011; 29:621-663.
49. Bisig B, de Reynies A, Bonnet C, Sujobert P, et al. CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. Haematologica 2013; 98:1250-1258.
50. Zhang Q, Wang H, Kantekure K, Paterson JC, et al. Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS. Blood 2011 ;118:3062-3071.
51. Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 2010; 28:57-78.
52. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013; 13:227-242.
53. Tanaka Y, Inoi T, Tozawa H, Yamamoto N, et al. A glycoprotein antigen detected with new monoclonal antibodies on the surface of human lymphocytes infected with human T-cell leukemia virus type-I (HTLV-I). Int J Cancer 1985 ; 36:549-555.
54. So T, Soroosh P, Eun SY, Altman A, et al. Antigen-independent signalosome of CARMA1, PKCtheta, and TNF receptor-associated factor 2 (TRAF2) determines NF-kappaB signaling in T cells. Proc Natl Acad Sci USA 2011; 108:2903-2908.
55. Tsuchiya T, Ohshima K, Karube K, Yamaguchi T, et al. Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: Comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood 2004; 103:236-241.
56. Iqbal J, Wright G, Wang C, Rosenwald A, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 2014; 123:2915-2923.
57. Dorfman DM, van den Elzen P, Weng AP, Shahsafaei A, et al. Differential expression of T-bet, a T-box transcription factor required for Th1 T-cell development, in peripheral T-cell lymphomas. Am J Clin Pathol 2003; 120:866-873.
58. Anderson MW, Zhao S, Freud AG, Czerwinski DK, et al. CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: Diagnostic and therapeutic implications. Am J Pathol 2012; 181:795-803.
59. Bossard C, Dobay MP, Parrens M, Lamant L, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: High correlation with mRNA levels. Blood 2014 ; 124:2983-2986.
60. Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: Novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006; 5:235-246.
61. Vahedi G, Takahashi H, Nakayamada S, Sun HW, et al. STATs shape the active enhancer landscape of T cell populations. Cell 2012 ; 151:981-993.
62. Abraham RM, Zhang Q, Odum N, Wasik MA. The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma. Cancer Biol Ther 2011;12:1019-1022.
63. Netchiporouk E, Litvinov IV, Moreau L, Gilbert M, et al. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. Cell Cycle 2014; 13:3331-3335.
64. Geskin LJ, Viragova S, Stolz DB, Fuschiotti P. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood. 2015; 125:2798-2805.
65. Nakagawa M, Schmitz R, Xiao W, Goldman CK, et al. Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. J Exp Med 2014 ; 211:2497-2505.
66. Laimer D, Dolznig H, Kollmann K, Vesely PW, et al. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med 2012; 18:1699-1704.
67. Piccaluga PP, Agostinelli C, Zinzani PL, Baccarani M, et al. Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified. Lancet Oncol 2005; 6:440.
68. Piccaluga PP, Rossi M, Agostinelli C, Ricci F, et al. Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway. Leukemia 2014; 28:1687-1697.
69. Ju W, Zhang M, Jiang JK, Thomas CJ, et al. CP-690, 550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood 2011; 117:1938-1946.
70. van der Fits L, Out-Luiting JJ, van Leeuwen MA, Samsom JN, et al. Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in Sezary syndrome. J Invest Dermatol 2012; 132:440-447.
71. Kiel MJ, Velusamy T, Rolland D, Sahasrabuddhe AA, et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood 2014 ; 124:1460-1472.
72. Bergmann AK, Schneppenheim S, Seifert M, Betts MJ, et al. Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer. 2014; 53:309-316.
73. Kucuk C, Jiang B, Hu X, Zhang W, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells. Nat Commun 2015; 6:6025.
74. Jerez A, Clemente MJ, Makishima H, Koskela H, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012; 120:3048-3057.
75. Chen YW, Guo T, Shen L, Wong KY, et al. Receptor-type tyrosine-protein phosphatase kappa directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma. Blood 2015; 125:1589-1600.
76. Odejide O, Weigert O, Lane AA, Toscano D, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 2014; 123:1293-1296.
77. Elliott NE, Cleveland SM, Grann V, Janik J, et al. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood 2011 ; 118:3911-3921.
78. Velusamy T, Kiel MJ, Sahasrabuddhe AA, Rolland D, et al. A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. Blood 2014; 124:3768-3771.
79. Huang W, August A. The signaling symphony: T cell receptor tunes cytokine-mediated T cell differentiation. J Leukoc Biol 2015; 97:477-485.
80. Tse E, Kwong YL. T-cell lymphoma: Microenvironment-related biomarkers. Semin Cancer Biol 2015;34:46-51.
81. Heid JB, Schmidt A, Oberle N, Goerdt S, et al. FOXP3+CD25- tumor cells with regulatory function in Sezary syndrome. J Invest Dermatol 2009; 129:2875-2885.
82. Wang G, Shi Y, Jiang X, Leak RK, et al. HDAC inhibition prevents white matter injury by modulating microglia/macrophage polarization through the GSK3beta/PTEN/Akt axis. Proc Natl Acad Sci USA 2015 ; 112:2853-2858.
83. Hume DA, MacDonald KP. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 2012; 119:1810-1820.
84. Croft M, Benedict CA, Ware CF. Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov 2013; 12:147-168.
85. Duvic M, Pinter-Brown LC, Foss FM, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood 2015; 125:1883-1889.
86. Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 2014 ; 123:3095-3100.
87. Wilcox RA, Sun DX, Novak A, et al. Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines. Leukemia 2010; 24:229-232.
88. Sharman J, Hawkins M, Kolibaba K, Boxer M, et al. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood 2015 ; 125:2336-2343.
89. Miller AT, Wilcox HM, Lai Z, Berg LJ. Signaling through Itk promotes T helper 2 differentiation via negative regulation of T-bet. Immunity 2004; 21:67-80.
90. Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013 ; 122:2539-2549. PubMed PMID: 23886836.
91. Wilcox RA. Cutaneous T-cell lymphoma: 2011 Update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86:928-948.
92. Vargas L, Hamasy A, Nore BF, Smith CI. Inhibitors of BTK and ITK: State of the new drugs for cancer, autoimmunity and inflammatory diseases. Scand J Immunol 2013; 78:130-139.
93. Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol 2013; 31:675-704.
94. Rolf J, Bell SE, Kovesdi D, Janas ML, et al. Phosphoinositide 3-kinase activity in T cells regulates the magnitude of the germinal center reaction. J Immunol 2010;185:4042-4052.
95. Martin-Sanchez E, Rodriguez-Pinilla SM, Sanchez-Beato M, Lombardia L, et al. Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. Haematologica 2013; 98:57-64.
96. Horwitz SM, Porcu P, Flinn IW, Kahl BS, et al. Duvelisib (IPI-145), a phosphoinositide-3-kinase-d, g inhibitor, shows activity in patients with relapsed/refractory T-cell lymphoma. Blood ASH Abstr 2014;124:Abstract #803.
97. Rahmani M, Aust MM, Benson EC, Wallace L, Friedberg J, Grant S. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo. Clin Cancer Res 2014; 20:4849-4860.
98. Zhang EY, Kong KF, Altman A. The yin and yang of protein kinase C-theta (PKCtheta): A novel drug target for selective immunosuppression. Adv Pharmacol 2013; 66:267-312.
99. Querfeld C, Rizvi MA, Kuzel TM, et al. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 2006; 126:1641-1647.
100. Querfeld C, Kuzel TM, Kim YH, Porcu P, et al. Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leuk Lymphoma 2011; 52:1474-1480.